Positives

• In severe eosinophilic asthma cohorts treated for 36 months, benralizumab reduced exacerbations by 89% and improved FEV1 by approximately 440 mL, supporting respiratory benefit in eosinophil-driven post-COVID lung disease MDPI.
  
  
• Patients on benralizumab who contracted COVID-19 generally had mild disease courses with minimal asthma deterioration, suggesting eosinophil depletion does not worsen viral outcomes PMC.
  
  

Negatives

• There are no published Long COVID trials of benralizumab; usage is restricted to patients who happen to also meet severe eosinophilic asthma criteria Respiratory-Research.
  
  

Hurdles & Side Effects

• Benralizumab (Fasenra) requires subcutaneous injection every 8 weeks at roughly $5,000 per dose, and insurers require documented eosinophil counts and severe asthma history before approval Respiratory-Therapy.